In Part 1 of this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss a new drug delivery system designed to deliver insulin molecules that are currently sold as commercial insulins to cells in the liver.
Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel type 2 diabetes technology, and oral therapy for obesity.
If you prefer to view the entire video, click here.
A full transcript of the entire video is available here.
To view other segments in this video:
Part 1: Diasome Pharmaceuticals Drug Delivery System
Part 2: Does insulin cause the liver to stop producing glucagon?
Part 3: Are your starting early Phase 3 trials?
Part 4: What are the benefits of a mixed insulin?
Part 5: How will this affect weight?
Part 6: How much have you seen in the reduction of insulin use?
Part 7: How are you going to market this?